Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study.

ABSTRACT:

Purpose

Bevacizumab combination treatment rechallenge in glioblastoma (GBM) patients who initially responded at recurrence has shown renewed responses in up to 60% of cases, with associated survival benefits. This study sought to characterise such repeat responders and identify predictive biomarkers.

Methods

A total of 254 IDHwt GBM patients treated with bevacizumab plus chemotherapy (BevCT) were evaluated for eligibility. Five patients met the inclusion criteria for this case study by exhibiting repeated responses to BevCT and having tumour tissue available for molecular analysis. Histopathological re-assessments were performed to confirm GBM diagnoses. Angiotensinogen (AGT) promoter methylation status was analysed in all primary tumour samples, while bulk RNA sequencing an

SUBMITTER: Lu MJS 

PROVIDER: S-EPMC12420756 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature